LBRX

Conviction 75HealthcareScan · Fri, Sep 25, 2026

Lb Pharmaceuticals Inc (LBRX) closed at $37.33 (-1.24%) on Sep 25, 2026. Price is below its 50-day and above its 200-day moving average. RSI(14) 29, RS Rating 96, -24.6% from its 52-week high, +82.6% year to date. Sector: Healthcare · Biotechnology.

LBRX$37.33-1.24%

ResistanceSupportVol 14

Vol MA14 311.74K

Jun 29Jul 16Aug 4Aug 20Sep 9Sep 25

LB PHARMACEUTICALS INCBiotechnologywww.lbpharma.us ↗

Price37.33

Change-1.24%

Gap-0.26%

Rel volume1.43×

Avg volume311.27K

Avg $ vol13.71M

SMA 2044.57

SMA 5043.41

SMA 20030.48

Price vs 50-14.02%

Price vs 200+22.49%

MA stackmixed

50/200 cross—

Supertrenddown · 43.76

RSI (14)29

MACD hist-1.12

MACD cross—

Stoch %K / %D3 / 3

ADX (14)29

+DI / −DI13 / 28

RSI divergence—

MACD divergence—

ATR %5.79%

ADR %4.72%

52w high49.48

52w low14.61

From 52w high-24.56%

Above 52w low+155.51%

New 52w highNo

SqueezeOff

Bollinger width32.66%

%B0.00

Donchian pos2.63%

Donchian high49.93

Donchian low36.99

AVWAP (52w high)44.54

vs AVWAP high-16.19%

AVWAP (52w low)28.95

vs AVWAP low+28.93%

OBV trendDown

Chaikin MF (20)-0.05

Today vs 20d1.43×

Avg vol (14d)314.22K

Avg vol (20d)311.27K

Avg $ vol (20d)13.71M

Market cap1.2B

RS Rating96 / 99

RS 3m (vs SPY)+11.14%

RS 6m (vs SPY)+32.61%

RS line new highNo

Trend template7/8

Technical rank59.6

1 week-12.10%

1 month-22.50%

3 months+16.95%

6 months+52.18%

1 year+148.87%

YTD+82.63%

P/E-47.78

P/B3.62

P/S—

P/FCF-34.15

EPS-3.13

Div yield—

ROE-7.58%

ROA-6.97%

Debt/Eq—

Current15.08

EV/EBITDA—

Gross margin—

Net margin—

Rev growth—

EPS growth60.06%

Price target56.57

Target upside51.54%

Analyst ratingBuy

Institutional96.01%

Ent. value921.12M

Revenue—

Net income-51.6M

Gross profit—

Free cash flow-35.26M

IndustryBiotechnology

ExchangeNasdaq

Shares out28.68M

Employees27

ListedThu, Sep 11, 2025

Free float23.84M

Float %83.2%

Short interest5.28M

Days to cover19.9d

Short volume53.2%

Squeeze score80 / 100

Next earnings—

EPS forecast—

Last EPS vs est−$1.71 vs −$0.84

Last surprise-103.6% miss

Setup gradeA

Conviction75 / 100

Pattern quality—

Tech rank59.6 / 100

Group rank50 / 100

Status laneNo active setup

Setup direction—

Pattern family

Resistance50.02

Support43.63

Days since event—

Candle confirm—

Financials as of Tue, Jun 30, 2026 · quarterly.

Congress activity

Disclosed STOCK Act trades in LBRX

All disclosures →

No recent disclosed trades by Congress in LBRX. STOCK Act filings can lag the trade by up to 45 days.

Insider activity

SEC Form 4 transactions in LBRX

Insider	Side	Shares	Value	Traded	Filed
Garland J. Scott Director · Stock Option (Right to Buy) · 2026-06-03	Grant	10K	$0	2026-06-03	2026-06-05
RUFFOLO ROBERT R Director · Stock Option (Right to Buy) · 2026-06-03	Grant	10K	$0	2026-06-03	2026-06-05
Hemrajani Rekha Director · Stock Option (Right to Buy) · 2026-06-03	Grant	10K	$0	2026-06-03	2026-06-05
Nussbaum Ran Director · Stock Option (Right to Buy) · 2026-06-03	Grant	10K	$0	2026-06-03	2026-06-05
Kane William P Jr Director · Stock Option (Right to Buy) · 2026-06-03	Grant	10K	$0	2026-06-03	2026-06-05
Lenz Robert A. Director · Stock Option (Right to Buy) · 2026-06-03	Grant	12.5K	$0	2026-06-03	2026-06-05
Luse Rebecca Director · Stock Option (Right to Buy) · 2026-06-03	Grant	10K	$0	2026-06-03	2026-06-05

SEC filings

EDGAR filings in LBRX · 10 recent

EDGAR →

Get daily signals & real-time alerts.

StockSetups scans ~12,300 US stocks & ETFs after every close and sorts every long setup into four ranked lanes — each with a trade plan — plus an always-on engine firing 35+ real-time intraday alerts. Free for 14 days, cancel in one click.

Start free — 14-day full access →

Educational data, not financial advice. Patterns, levels and the trade plan are algorithmic, not a recommendation to trade.